Literature DB >> 24961351

Detection of TMPRSS2-ERG fusion gene in benign prostatic hyperplasia.

S Velaeti1, E Dimitriadis, K Kontogianni-Katsarou, A Savvani, E Sdrolia, G Pantazi, S Stefanakis, T Trangas, N Pandis, K Petraki.   

Abstract

The Ets-related gene fusions are among the most common molecular alterations in prostate cancer (PCa) and are detected in more than 50 % of PCas. Transmembrane protease serine 2 and Ets-related gene fusion (TMPRSS2-ERG) is the most frequently identified chimeric gene and has been associated with undifferentiated and invasive phenotypes. TMPRSS2-ERG has also been detected in prostate intraepithelial neoplasia (PIN) lesions and more rarely in benign prostatic hyperplasia (BPH) regions mainly in PCa-bearing glands. The possibility that the fusion TMPRSS2-ERG may be present in BPH samples in the absence of apparent PCa was addressed. Out of 115 BPH samples, three were found positive employing RT-PCR. The presence of the fusion gene was confirmed by FISH for these samples, and an additional four samples were found to carry the TMPRSS2-ERG fusion out of 43 tested by the later approach. The presence of the TMPRSS2-ERG fusion did not result in altered expression of 12 putative downstream targets. These findings indicate that TMPRSS2-ERG may or may not lead to PCa development.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24961351     DOI: 10.1007/s13277-014-2250-0

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  31 in total

1.  TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.

Authors:  Karin G Hermans; Ronald van Marion; Herman van Dekken; Guido Jenster; Wytske M van Weerden; Jan Trapman
Journal:  Cancer Res       Date:  2006-11-15       Impact factor: 12.701

2.  Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells.

Authors:  Nuria Coll Bastus; Lara K Boyd; Xueying Mao; Elzbieta Stankiewicz; Sakunthala C Kudahetti; R Tim D Oliver; Daniel M Berney; Yong-Jie Lu
Journal:  Cancer Res       Date:  2010-10-14       Impact factor: 12.701

3.  Cancer-associated changes in the expression of TMPRSS2-ERG, PCA3, and SPINK1 in histologically benign tissue from cancerous vs noncancerous prostatectomy specimens.

Authors:  Riina-Minna Väänänen; Hans Lilja; Leni Kauko; Pauliina Helo; Henna Kekki; Angel M Cronin; Andrew J Vickers; Martti Nurmi; Kalle Alanen; Anders Bjartell; Kim Pettersson
Journal:  Urology       Date:  2014-02       Impact factor: 2.649

4.  ETS rearrangements and prostate cancer initiation.

Authors:  Brett S Carver; Jennifer Tran; Zhenbang Chen; Arkaitz Carracedo-Perez; Andrea Alimonti; Caterina Nardella; Anuradha Gopalan; Peter T Scardino; Carlos Cordon-Cardo; William Gerald; Pier Paolo Pandolfi
Journal:  Nature       Date:  2009-02-12       Impact factor: 49.962

5.  TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia.

Authors:  Kyung Park; James T Dalton; Ramesh Narayanan; Christopher E Barbieri; Michael L Hancock; David G Bostwick; Mitchell S Steiner; Mark A Rubin
Journal:  J Clin Oncol       Date:  2013-12-02       Impact factor: 44.544

Review 6.  ETS gene fusions in prostate cancer: from discovery to daily clinical practice.

Authors:  Scott A Tomlins; Anders Bjartell; Arul M Chinnaiyan; Guido Jenster; Robert K Nam; Mark A Rubin; Jack A Schalken
Journal:  Eur Urol       Date:  2009-04-24       Impact factor: 20.096

7.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.

Authors:  Brett S Carver; Jennifer Tran; Anuradha Gopalan; Zhenbang Chen; Safa Shaikh; Arkaitz Carracedo; Andrea Alimonti; Caterina Nardella; Shohreh Varmeh; Peter T Scardino; Carlos Cordon-Cardo; William Gerald; Pier Paolo Pandolfi
Journal:  Nat Genet       Date:  2009-04-26       Impact factor: 38.330

Review 8.  Integrative biology of prostate cancer progression.

Authors:  Scott A Tomlins; Mark A Rubin; Arul M Chinnaiyan
Journal:  Annu Rev Pathol       Date:  2006       Impact factor: 23.472

9.  Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts.

Authors:  Jianghua Wang; Yi Cai; Wendong Yu; Chengxi Ren; David M Spencer; Michael Ittmann
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

10.  TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.

Authors:  Sven Perner; Juan-Miguel Mosquera; Francesca Demichelis; Matthias D Hofer; Pamela L Paris; Jeff Simko; Colin Collins; Tarek A Bismar; Arul M Chinnaiyan; Angelo M De Marzo; Mark A Rubin
Journal:  Am J Surg Pathol       Date:  2007-06       Impact factor: 6.394

View more
  3 in total

Review 1.  Clinically relevant genetic characterization of prostate tumors: how close are we to the goal?

Authors:  Yuri Tolkach; Florian Imkamp; Konstantin Godin; Hendrik Van Poppel
Journal:  Korean J Urol       Date:  2015-01-30

Review 2.  Discovery and Classification of Fusion Transcripts in Prostate Cancer and Normal Prostate Tissue.

Authors:  Jian-Hua Luo; Silvia Liu; Ze-Hua Zuo; Rui Chen; George C Tseng; Yan P Yu
Journal:  Am J Pathol       Date:  2015-05-09       Impact factor: 4.307

Review 3.  The oncogene ERG: a key factor in prostate cancer.

Authors:  P Adamo; M R Ladomery
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.